Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | Director | January 03, 2023 | January 03, 2023 |
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Director | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date January 03, 2023 · Filed January 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common Shares, no par value per shareSEC Table I · non-derivative | Direct | 73,288 |
Reported balance
After 2023-01-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 17,156 · Balance 73,288 F1: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $26,250. F2: Includes 28,338 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $26,250.
F2: Includes 28,338 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan.
Tenaya Therapeutics, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2036-05-27 | Direct | 120,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 120,000 · Balance 120,000 F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Terns Pharmaceuticals, Inc.
Report date May 05, 2026 · Filed May 05, 2026
Section 16 reporting ended · disclosed 2026-05-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-05 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-05-05 · Other · Disposed 146,614 · Balance 0 F1: Includes 7,638 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan since the reporting person's Form 4 filed on March 17, 2026. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-05 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-05-05 · Disposition to issuer · Disposed 150,000 · Balance 0 F4: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding, whether or not vested, was cancelled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Merger Consideration and the total number of Shares subject to such RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement). |
| Common StockSEC Table I · non-derivative | IndirectTrust | 0 |
Reported balance
After 2026-05-05 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-05-05 · Other · Disposed 8,319 · Balance 0 F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. F3: The Reporting Person beneficially owns these shares indirectly through the Amy L Burroughs 2017 Trust. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 | Direct | 0 |
Reported balance
After 2026-05-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-05 · Disposition to issuer · Disposed 955,534 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.31 | Direct | 0 |
Reported balance
After 2026-05-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-05 · Disposition to issuer · Disposed 1,250,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.18 | Direct | 0 |
Reported balance
After 2026-05-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-05 · Disposition to issuer · Disposed 300,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 7,638 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan since the reporting person's Form 4 filed on March 17, 2026.
F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
F3: The Reporting Person beneficially owns these shares indirectly through the Amy L Burroughs 2017 Trust.
F4: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding, whether or not vested, was cancelled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Merger Consideration and the total number of Shares subject to such RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement).
F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed May 29, 2026 23:07 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 120,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001193125-26-249052 · ownership.xml · derivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2036-05-27 F1 · derivative.exercise_date: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| May 05, 2026 Filed May 5, 2026 21:00 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Disposition to issuerStock Option (Right to Buy) · Derivative | 300,000 | Not disclosed Strike: $37.18 | Not disclosed |
DisclosureSEC source: 0001872564-26-000010 · primarydocument.xml · derivative · entry 6 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires not disclosed F5 · shares: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. Read SEC document |
| May 05, 2026 Filed May 5, 2026 21:00 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,250,000 | Not disclosed Strike: $7.31 | Not disclosed |
DisclosureSEC source: 0001872564-26-000010 · primarydocument.xml · derivative · entry 5 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250,000 shares Expires not disclosed F5 · shares: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. Read SEC document |
| May 05, 2026 Filed May 5, 2026 21:00 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Disposition to issuerStock Option (Right to Buy) · Derivative | 955,534 | Not disclosed Strike: $4.64 | Not disclosed |
DisclosureSEC source: 0001872564-26-000010 · primarydocument.xml · derivative · entry 4 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 955,534 shares Expires not disclosed F5 · shares: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. Read SEC document |
| May 05, 2026 Filed May 5, 2026 21:00 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Disposition to issuerCommon Stock | 150,000 | $53.00 | $7,950,000.00 |
DisclosureSEC source: 0001872564-26-000010 · primarydocument.xml · nonDerivative · entry 3 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding, whether or not vested, was cancelled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Merger Consideration and the total number of Shares subject to such RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement). Read SEC document |
| May 05, 2026 Filed May 5, 2026 21:00 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | OtherCommon Stock | 8,319 | $53.00 | $440,907.00 |
DisclosureSEC source: 0001872564-26-000010 · primarydocument.xml · nonDerivative · entry 2 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 0 F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. F3 · ownership.nature: The Reporting Person beneficially owns these shares indirectly through the Amy L Burroughs 2017 Trust. Read SEC document |
| May 05, 2026 Filed May 5, 2026 21:00 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | OtherCommon Stock | 146,614 | $53.00 | $7,770,542.00 |
DisclosureSEC source: 0001872564-26-000010 · primarydocument.xml · nonDerivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 7,638 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan since the reporting person's Form 4 filed on March 17, 2026. F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 22:10 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,583 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001872564-26-000008 · primarydocument.xml · derivative · entry 5 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 955,534 Underlying: Common Stock · 14,583 shares Expires 2035-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 22:10 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | SaleCommon Stock | 2,770 | $47.30 | $131,027.65 |
DisclosureSEC source: 0001872564-26-000008 · primarydocument.xml · nonDerivative · entry 3 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 288,976 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. F3 · price: This sale price represents the weighted average sale price of the shares sold ranging from $47.01 to $47.91 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 22:10 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | SaleCommon Stock | 11,813 | $46.57 | $550,080.61 |
DisclosureSEC source: 0001872564-26-000008 · primarydocument.xml · nonDerivative · entry 2 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 291,746 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $46.01 to $47.005 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 22:10 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Exercise / conversionCommon Stock | 14,583 | $4.64 | $67,665.12 |
DisclosureSEC source: 0001872564-26-000008 · primarydocument.xml · nonDerivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 303,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 00:01 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,583 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001872564-26-000006 · primarydocument.xml · derivative · entry 6 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 970,117 Underlying: Common Stock · 14,583 shares Expires 2035-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 00:01 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | SaleCommon Stock | 4,083 | $39.80 | $162,501.36 |
DisclosureSEC source: 0001872564-26-000006 · primarydocument.xml · nonDerivative · entry 4 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 288,976 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. F4 · price: This sale price represents the weighted average sale price of the shares sold ranging from $39.54 to $40.25 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 00:01 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | SaleCommon Stock | 8,159 | $39.22 | $319,963.34 |
DisclosureSEC source: 0001872564-26-000006 · primarydocument.xml · nonDerivative · entry 3 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 293,059 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. F3 · price: This sale price represents the weighted average sale price of the shares sold ranging from $38.54 to $39.53 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 00:01 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | SaleCommon Stock | 2,341 | $38.07 | $89,114.38 |
DisclosureSEC source: 0001872564-26-000006 · primarydocument.xml · nonDerivative · entry 2 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,218 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $37.54 to $38.53 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 00:01 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Exercise / conversionCommon Stock | 14,583 | $4.64 | $67,665.12 |
DisclosureSEC source: 0001872564-26-000006 · primarydocument.xml · nonDerivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 303,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:22 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,583 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001872564-26-000004 · primarydocument.xml · derivative · entry 11 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 984,700 Underlying: Common Stock · 14,583 shares Expires 2035-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:22 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,083 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001872564-26-000004 · primarydocument.xml · derivative · entry 10 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 999,283 Underlying: Common Stock · 27,083 shares Expires 2035-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:22 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,083 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001872564-26-000004 · primarydocument.xml · derivative · entry 9 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,026,366 Underlying: Common Stock · 27,083 shares Expires 2035-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:22 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | SaleCommon Stock | 7,521 | $37.53 | $282,230.04 |
DisclosureSEC source: 0001872564-26-000004 · primarydocument.xml · nonDerivative · entry 6 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 288,976 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. F4 · price: This sale price represents the weighted average sale price of the shares sold ranging from $37.45 to $37.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:22 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | SaleCommon Stock | 61,228 | $37.02 | $2,266,372.79 |
DisclosureSEC source: 0001872564-26-000004 · primarydocument.xml · nonDerivative · entry 5 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 296,497 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. F3 · price: This sale price represents the weighted average sale price of the shares sold ranging from $36.45 to $37.445 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:22 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Exercise / conversionCommon Stock | 14,583 | $4.64 | $67,665.12 |
DisclosureSEC source: 0001872564-26-000004 · primarydocument.xml · nonDerivative · entry 4 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 357,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:22 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Exercise / conversionCommon Stock | 27,083 | $4.64 | $125,665.12 |
DisclosureSEC source: 0001872564-26-000004 · primarydocument.xml · nonDerivative · entry 3 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 343,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:22 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Exercise / conversionCommon Stock | 27,083 | $4.64 | $125,665.12 |
DisclosureSEC source: 0001872564-26-000004 · primarydocument.xml · nonDerivative · entry 2 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 316,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. Read SEC document |
| January 14, 2026 Filed Jan 16, 2026 22:22 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001872564-26-000004 · primarydocument.xml · derivative · entry 8 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-01-13 F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| January 14, 2026 Filed Jan 16, 2026 22:22 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001872564-26-000004 · primarydocument.xml · nonDerivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 288,976 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). 25% of the RSUs vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/16th of the total number of shares vest quarterly thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 01:26 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Exercise / conversionRestricted Stock Unit · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001872564-26-000002 · primarydocument.xml · derivative · entry 6 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive, upon vesting, one share of common stock. F6 · derivative.exercise_date: The restricted stock unit award was granted on March 1, 2024. The restricted stock unit award was subject to vesting as to 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equaled or exceeded $15.00 per share and as to the remaining 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equaled or exceeded $20.00 per share. The performance criteria for the specified milestones were determined to have been achieved by the Compensation Committee as to 100% of the underlying shares, and the delivery and release of the underlying shares occurred on January 5, 2026. F6 · derivative.expiration_date: The restricted stock unit award was granted on March 1, 2024. The restricted stock unit award was subject to vesting as to 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equaled or exceeded $15.00 per share and as to the remaining 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equaled or exceeded $20.00 per share. The performance criteria for the specified milestones were determined to have been achieved by the Compensation Committee as to 100% of the underlying shares, and the delivery and release of the underlying shares occurred on January 5, 2026. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 01:26 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | SaleCommon Stock | 71,339 | $38.10 | $2,718,229.92 |
DisclosureSEC source: 0001872564-26-000002 · primarydocument.xml · nonDerivative · entry 3 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,976 F2 · kind: Represents shares of common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person. Such sales do not represent a discretionary trade by the Reporting Person. F3 · price: This sale price represents the weighted average sale price of the shares sold ranging from $37.43 to $39.595 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 01:26 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Exercise / conversionCommon Stock | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001872564-26-000002 · primarydocument.xml · nonDerivative · entry 2 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive, upon vesting, one share of common stock. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:26 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,551 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001872564-26-000002 · primarydocument.xml · derivative · entry 5 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,053,449 Underlying: Common Stock · 21,551 shares Expires 2035-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:26 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | Exercise / conversionCommon Stock | 21,551 | $4.64 | $99,996.64 |
DisclosureSEC source: 0001872564-26-000002 · primarydocument.xml · nonDerivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2025 Filed Jun 25, 2025 22:08 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | PurchaseCommon Stock | 23,314 | $3.87 | $90,229.84 |
DisclosureSEC source: 0001562180-25-005077 · primarydocument.xml · nonDerivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,083 F1 · balance_after: Includes 4,160 shares acquired by the reporting person under the Issuer's 2021 Employee Stock Purchase Plan on May 31, 2025. Read SEC document |
| May 29, 2025 Filed May 30, 2025 22:52 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 107,400 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000950170-25-079948 · ownership.xml · derivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,400 Underlying: Common Stock · 107,400 shares Expires 2035-05-28 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 00:25 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | GrantStock Option (Right to Buy) · Derivative | 1,075,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001562180-25-000851 · primarydocument.xml · derivative · entry 2 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,075,000 Underlying: Common Stock · 1,075,000 shares Expires 2035-01-29 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 23:04 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | PurchaseCommon Stock | 15,450 | $7.15 | $110,467.50 |
DisclosureSEC source: 0001562180-24-008254 · primarydocument.xml · nonDerivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,099 F1 · balance_after: Includes 3,649 shares acquired by the reporting person under the Issuer's 2021 Employee Stock Purchase Plan ("ESPP") on November 30, 2024. Read SEC document |
| November 30, 2024 Filed Feb 4, 2025 00:25 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | PurchaseCommon Stock | 510 | $5.11 | $2,606.10 |
DisclosureSEC source: 0001562180-25-000851 · primarydocument.xml · nonDerivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,609 F1 · shares: Includes an additional 510 shares acquired by the reporting person under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2024 that was not previously reported on the reporting person's Form 4 filed on December 9, 2024 due to an administrative error. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 00:35 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 34,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0000950170-24-116058 · ownership.xml · derivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2034-10-17 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 31, 2025, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:01 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | GrantStock Option (Right to buy) · Derivative | 1,250,000 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001562180-24-002316 · primarydocument.xml · derivative · entry 2 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires 2034-02-28 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:01 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | GrantRestricted Stock Unit · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-002316 · primarydocument.xml · derivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of common stock. F2 · derivative.exercise_date: The restricted stock unit award has a four-year term and vests based on the achievement of milestones stock prices with respect to the Issuer's common stock, subject to the Reporting Person's continued employment through the applicable vesting milestones. The restricted stock unit award vests as to 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equals or exceeds $15.00 per share and as to the remaining 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equals or exceeds $20.00 per share; provided that vesting shall not be deemed to occur earlier than the first anniversary of the Reporting Person's first day of employment and that vesting must be achieved on or before the fourth anniversary of the first day of employment. F2 · derivative.expiration_date: The restricted stock unit award has a four-year term and vests based on the achievement of milestones stock prices with respect to the Issuer's common stock, subject to the Reporting Person's continued employment through the applicable vesting milestones. The restricted stock unit award vests as to 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equals or exceeds $15.00 per share and as to the remaining 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equals or exceeds $20.00 per share; provided that vesting shall not be deemed to occur earlier than the first anniversary of the Reporting Person's first day of employment and that vesting must be achieved on or before the fourth anniversary of the first day of employment. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 00:09 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 14,766 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-23-036502 · doc4.xml · derivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,766 Underlying: Common Stock · 14,766 shares Expires 2033-06-08 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 21:36 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 17,156 | $1.53 | $26,248.68 |
DisclosureSEC source: 0001235802-23-000003 · primary_doc.xml · nonDerivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,288 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $26,250. F2 · balance_after: Includes 28,338 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 23:20 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 40,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-22-060234 · doc4.xml · derivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-12-04 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/36th of the total number of shares subject to the option on the one (1) month anniversary of the Transaction Date and 1/36th of the total number of shares subject to the option on each monthly anniversary thereafter, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:58 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 13,222 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001235802-22-000074 · primary_doc.xml · derivative · entry 2 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,222 Underlying: Common Shares · 13,222 shares Expires 2032-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| January 03, 2022 Filed Jan 3, 2022 21:39 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 11,182 | $3.58 | $40,031.56 |
DisclosureSEC source: 0001235802-22-000004 · primary_doc.xml · nonDerivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,132 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $40,000. F2 · balance_after: Includes 11,182 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:11 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 44,950 | $3.15 | $141,592.50 |
DisclosureSEC source: 0001235802-21-000101 · primary_doc.xml · nonDerivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,950 Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:35 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 18,786 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001235802-21-000079 · primary_doc.xml · derivative · entry 2 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,786 Underlying: Common Shares · 18,786 shares Expires 2031-07-14 F1 · derivative.exercise_date: Vests in twelve nearly equal quarterly installments over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.